CEO, President, Glaukos
WHY: Leads maker of devices to treat glaucoma; $2.3B value up 20% year-to-date through late 2019, more than double since mid-2015 IPO. Building-out new HQ in Aliso Viejo.
RECENT: Expanding into pharma-based eyecare with $400M buy of Mass.-based Avedro (Nasdaq: AVDR), licensing of technology from privately held Intratus in San Diego.
NOTABLE: With organic, acquisitive growth, looks to see roughly $325M revenue, 2020.
FUN FACTS: Played QB in high school, strong safety in college. Favorite book: “The Five People You Meet in Heaven.” TV show: “Seinfeld.”